Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03

To Learn More Call
201-510-0910

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Gastrointestinal

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE 203

To Learn More Call
201-510-0910

A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or metastatic Non-Small Cell Lung Cancer

Sponsor
Janssen

Protocol Number
54767414LUC2001

To Learn More Call
201-510-0910

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Type of Cancer
Lung

Site
Bethesda

Sponsor
Bristol Myers-Squibb

Protocol Number
CA209384

To Learn More Call
201-510-0910

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Site
Bethesda

Protocol Number
INCB 50465-102

To Learn More Call
201-510-0910

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized management of Patients

Sponsor
Tesaro

Protocol Number
MTG-022

To Learn More Call
201-510-0910

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
Seattle Genetics

Protocol Number
SGN35-015

To Learn More Call
201-510-0910

Phase III, randomized, open-label, comparative safety and efficacy trial of IV iron isomaltoside (Monofer®) and iron sucrose (Venofer) in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or in whom the hemoglobin measurement in Investigators’ opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
P-MONOFER-IDA-03